Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MET-GGGi
- Development stage
- Preclinical
- Lead developer
- D&D Pharmatech
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
MET-GGGi is a long-acting peptide triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. Developed by D&D Pharmatech, the drug utilizes the company's proprietary long-acting technology to extend its half-life for injectable administration. It is currently in preclinical development for the treatment of obesity, aiming to leverage the synergistic effects of all three metabolic hormones to maximize weight loss and improve metabolic health. The 'i' in the name distinguishes this injectable formulation from the company's oral version, MET-GGGo.
02
Targets
Beyond the preview
Go deeper on MET-GGGi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MET-GGGi.